HealthQuill Pulmonary arterial hypertension
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its ā€œrobust efficacy,ā€ according to a company statement.
Drugs Health Medical

Merck & Co stops final-stage drug trial for treating PAH

Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its ā€œrobust efficacy,ā€ according.

Read More
Merckā€™s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by the FDA.
Drugs Health Pharma

Merck gets priority review nod from USFDA for hypertension drugĀ 

HQ Team September 28, 2023: Merckā€™s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by.

Read More
Merck announced its experimental trial on patients with pulmonary arterial hypertension had led to an extension in walking distance and reduced exacerbating the condition by 84%.
Drugs Medical Pharma

Merck says trial hypertension drug enhances patientsā€™ walk timeļæ¼

Merck announced its experimental trial on patients with pulmonary arterial hypertension had led to an extension in walking distance and reduced exacerbating the.

Read More